UY35947A - Compuestos antagonistas selectivos de n-metil-d-aspartato (nmda) subtipo nr2b y composiciones que los contienen - Google Patents

Compuestos antagonistas selectivos de n-metil-d-aspartato (nmda) subtipo nr2b y composiciones que los contienen

Info

Publication number
UY35947A
UY35947A UY0001035947A UY35947A UY35947A UY 35947 A UY35947 A UY 35947A UY 0001035947 A UY0001035947 A UY 0001035947A UY 35947 A UY35947 A UY 35947A UY 35947 A UY35947 A UY 35947A
Authority
UY
Uruguay
Prior art keywords
nr2b
subtipo
nmda
aspartate
methyl
Prior art date
Application number
UY0001035947A
Other languages
English (en)
Inventor
Lorin A Thompson Iii
John E Macor
King Dalton
Shi Janliang
Thangathirupathy Srinivasan
Jayakumar Sankara Warrier
Islam Imadul
Original Assignee
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporación Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Publication of UY35947A publication Critical patent/UY35947A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La descripción se refiere en general a compuestos de la fórmula I, incluyendo sus sales, así como composiciones y métodos de uso de los compuestos. Los compuestos son ligandos del receptor NR2B y pueden ser útiles para el tratamiento de diversos trastornos del sistema nervioso central.
UY0001035947A 2014-01-09 2015-01-09 Compuestos antagonistas selectivos de n-metil-d-aspartato (nmda) subtipo nr2b y composiciones que los contienen UY35947A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461925363P 2014-01-09 2014-01-09

Publications (1)

Publication Number Publication Date
UY35947A true UY35947A (es) 2015-07-31

Family

ID=52463126

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035947A UY35947A (es) 2014-01-09 2015-01-09 Compuestos antagonistas selectivos de n-metil-d-aspartato (nmda) subtipo nr2b y composiciones que los contienen

Country Status (27)

Country Link
US (10) US9221796B2 (es)
EP (1) EP3092224B1 (es)
JP (1) JP6543259B2 (es)
KR (1) KR102311518B1 (es)
CN (1) CN106061961B (es)
AR (1) AR099071A1 (es)
AU (1) AU2015205001A1 (es)
CA (1) CA2936293A1 (es)
CL (1) CL2016001763A1 (es)
DK (1) DK3092224T3 (es)
EA (1) EA201691413A1 (es)
ES (1) ES2693250T3 (es)
HR (1) HRP20181585T1 (es)
HU (1) HUE041986T2 (es)
IL (1) IL246599A0 (es)
LT (1) LT3092224T (es)
MX (1) MX2016008898A (es)
PE (1) PE20160933A1 (es)
PL (1) PL3092224T3 (es)
PT (1) PT3092224T (es)
RS (1) RS57830B1 (es)
SG (1) SG11201605618WA (es)
SI (1) SI3092224T1 (es)
TR (1) TR201815579T4 (es)
TW (1) TWI640515B (es)
UY (1) UY35947A (es)
WO (1) WO2015105772A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221796B2 (en) * 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists
AU2016340239A1 (en) * 2015-10-14 2018-05-31 Bristol-Myers Squibb Company Selective NR2B antagonists
EP3362441B1 (en) 2015-10-14 2020-08-12 Bristol-Myers Squibb Company Selective nr2b antagonists
CN108203404A (zh) * 2018-03-02 2018-06-26 上海博邦医药科技有限公司 (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法
US10781172B2 (en) 2018-06-21 2020-09-22 Northwestern University Catalysts and methods for enantioselective conjugate additions of amines to unsaturated electrophiles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2744448B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
AU3818900A (en) 1999-04-14 2000-11-02 F. Hoffmann-La Roche Ag Process for the preparation of substituted piperidines
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
KR20020093950A (ko) * 2000-04-26 2002-12-16 워너-램버트 캄파니 아형 선택적인 ｎｍｄａ 수용체 길항제로서의시클로헥실아민 유도체
WO2003035641A1 (fr) 2001-10-22 2003-05-01 Shionogi & Co., Ltd. Nouveau derive carbamoyl-pyrrolidone
CA2527093C (en) 2003-06-04 2009-10-20 Merck & Co., Inc. 3-fluoro-piperidines as nmda/nr2b antagonists
WO2005035523A1 (en) 2003-10-08 2005-04-21 Pfizer Japan Inc. Fused lactam compounds
EP1988077A4 (en) 2006-02-23 2009-09-02 Shionogi & Co NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS
CN101815518B (zh) 2007-06-29 2013-01-09 埃莫里大学 用于神经保护的nmda受体拮抗剂
US9221796B2 (en) * 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists

Also Published As

Publication number Publication date
IL246599A0 (en) 2016-08-31
AU2015205001A1 (en) 2016-08-18
JP6543259B2 (ja) 2019-07-10
CL2016001763A1 (es) 2017-02-10
HRP20181585T1 (hr) 2018-12-14
CN106061961A (zh) 2016-10-26
DK3092224T3 (en) 2018-11-26
EP3092224A1 (en) 2016-11-16
PE20160933A1 (es) 2016-09-10
TR201815579T4 (tr) 2018-11-21
KR20160105885A (ko) 2016-09-07
ES2693250T3 (es) 2018-12-10
US20170258777A1 (en) 2017-09-14
AR099071A1 (es) 2016-06-29
JP2017502063A (ja) 2017-01-19
US20160081995A1 (en) 2016-03-24
MX2016008898A (es) 2016-10-04
US20180000807A1 (en) 2018-01-04
US20180110766A1 (en) 2018-04-26
TW201613884A (en) 2016-04-16
KR102311518B1 (ko) 2021-10-08
PT3092224T (pt) 2018-11-14
RS57830B1 (sr) 2018-12-31
CA2936293A1 (en) 2015-07-16
EP3092224B1 (en) 2018-08-22
SG11201605618WA (en) 2016-08-30
US20150191452A1 (en) 2015-07-09
US20190117638A1 (en) 2019-04-25
US20180250283A1 (en) 2018-09-06
US20190314358A1 (en) 2019-10-17
PL3092224T3 (pl) 2019-05-31
HUE041986T2 (hu) 2019-06-28
US20210121453A1 (en) 2021-04-29
CN106061961B (zh) 2018-12-18
US20200163949A1 (en) 2020-05-28
WO2015105772A1 (en) 2015-07-16
EA201691413A1 (ru) 2016-10-31
TWI640515B (zh) 2018-11-11
LT3092224T (lt) 2018-10-25
US9221796B2 (en) 2015-12-29
SI3092224T1 (sl) 2018-11-30

Similar Documents

Publication Publication Date Title
CL2018003474A1 (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen.
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20170384A (es) Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
ECSP16000724A (es) Carboxamidas de anillo de 4 miembros empleadas como nematicidas
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
BR112016025423A2 (pt) compostos e composições como agonistas de receptores do tipo toll 7
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
CR20160374A (es) Ciclopentanos sustituidos en 1,2 como antagonistas del receptor de orexina
NI201700129A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
UY35947A (es) Compuestos antagonistas selectivos de n-metil-d-aspartato (nmda) subtipo nr2b y composiciones que los contienen
UY36195A (es) Amidas de benzoxazinona como reguladores del receptor mineralocorticoide
CL2016002240A1 (es) Derivados de piperidina como antagonista de receptores de orexina
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
CL2015003761A1 (es) Derivados de etinil como antagonistas de receptor metabotrópico de glutamato.
UY33722A (es) Oxazolidinonas como moduladores de mglur5